Use of Tranexamic Acid to Prevent Postpartum Hemorrhage in Women Undergoing Cesarean Delivery: A Meta-Analysis
ACOG ePoster. Vasichko P. Apr 27, 2018; 211546
Paula Vasichko
Paula Vasichko
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
Introduction: Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality. Multiple clinical trials evaluated tranexmic acid (TXA) for treatment and prevention of PPH, but there is currently insufficient evidence to support prophylactic use. Our objective was to conduct a systematic review and meta-analysis using available data from randomized clinical trials (RCT) that evaluated the efficacy of TXA prophylaxis during cesarean section.

Methods: A systematic literature review was conducted using PUBMED and MEDLINE 1966-2017 with relevant search terms. Secondary citations from retrieved papers were also reviewed. Outcome data from RCTs were abstracted and meta-analysis performed using the Mantel-Haenszel fixed effects model with test of heterogeneity.

Results: 27 RCTs were identified for prophylactic use of TXA at cesarean section; which included 4728 women. Only a single study included women at high risk for PPH. Administration of TXA was significantly associated with reduction of mean estimated blood loss (EBL) (27 studies, n=4728, OR 0.45, 95% CI 0.41–0.50), PPH1000 mL (6 studies, n= 1986, OR 0.27, 95% CI 0.18-0.43), use of blood transfusions (12 studies, n=2813, OR 0.33, 95% CI 0.20-0.54), and need for other medical interventions (9 studies, n=2577, OR 0.39, 95% CI 0.29-0.53). Only 4 cases of VTE in 4366 women were reported which occurred similarly in controls and TXA.

Conclusion/Implications: In an overall low risk patient population, prophylactic TXA at cesarean section was effective in reducing mean EBL, PPH1000, blood transfusions, and need for other medical interventions. Additional research is needed to elucidate optimal regimens to maximize efficacy and minimize risk.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings